Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

Update: 2024-07-22

Description

In this episode I chat with Dr Sarah Hein, co-founder and CEO of March Biosciences, a Houston Based biotech developing cell therapies for T-cell malignancies. Sarah is an old friend and colleague from our days as trainees at Baylor College of Medicine, where we both circulated among those with ambitions of entrepreneurship. Sarah has definitely made good in that regard, as a serial entrepreneur deeply enmeshed in Houston’s growing life sciences and healthtech ecosystem.

Episode 37 links:

⁠⁠⁠⁠TPM E37⁠⁠⁠ for highlights and links from this episode >⁠

⁠Genialis’ Upcoming Events⁠

⁠Genialis™ krasID

Comments

In Channel

Mida Pezeshkian, Stema_cg | Launching products in healthcare: The most important framework is flexibility | TPM podcast #49

2025-08-2944:30

Michael Montalto, Amgen | How to have the biggest impact on patients: a career of invention, innovation, and implementation | TPM podcast #48

2025-07-2443:24

Tom Neyarapally, Archetype Therapeutics | A new paradigm for generative AI drug discovery: more accurate shots on a much wider goal | TPM podcast #47

2025-06-2442:43

Stéphane Budel, DeciBio | Precision medicine is our future and our fate | TPM podcast #46

2025-05-1950:02

Anna Berkenblit & Sudheer Doss, PanCAN | On a mission to beat an ignoble killer: pancreatic cancer | TPM podcast #45

2025-04-2246:10

Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44

2025-03-2838:35

Ryan Fukushima | Reinventing diagnostics: The superpower of not knowing what can’t be done | TPM #43

2025-02-2643:19

The journey to the top of life sciences technology: a lifetime of listening and learning | Talking Precision Medicine #42

2025-01-3147:34

The view from 30,000: Healthcare & life science AI in the cloud | Talking Precision Medicine #41

2024-12-1837:10

What’s in a digital twin? Inventing new kinds of AI for biomedicine | Talking Precision Medicine #40

2024-11-1547:02

Leave No Patient Behind—R&D Tools and Cutting Edge Diagnostics that Span the Globe | Talking Precision Medicine #39

2024-10-0835:38

Zola-007: Giving T-cells the license to kill | Talking Precision Medicine #38

2024-08-2944:06

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

2024-07-2239:01

Tackling healthcare disparities and bridging the digital divide: it doesn’t have to be so hard | Talking Precision Medicine #36

2024-05-2444:13

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

2024-04-1231:27

Professional grade software — a key ingredient in cutting edge biomedical discovery | Talking Precision Medicine #34

2023-12-1431:38

New Medicines from Evolutionary Pathways: Using Comparative Genomics to Treat Human Disease | Talking Precision Medicine #33

2023-10-2742:45

To achieve personalized medicine, start by getting the dose right | Talking Precision Medicine #32

2023-08-0239:13

AI and Ethics in Healthtech: Who is Innovating Most? | Talking Precision Medicine #31

2023-06-2934:41

People first: building a company that inspires impactful work | Talking Precision Medicine #30

2023-05-3151:06

00:00

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

#box-pro-ellipsis-175885595281251{-webkit-line-clamp:2;}Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

Genialis

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37